SCHEMBL294106

SCHEMBL294106

Cc1cnc2[nH]ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 7/20 0.55
AXL P30530 3/20 0.55
PIK3CA P42336 3/20 0.53
PIK3CD O00329 1/20 0.53
PIK3CB P42338 1/20 0.53
PIK3CG P48736 1/20 0.53
RIPK1 Q13546 3/20 0.51
KDR P35968 3/20 0.49
FGFR1 P11362 2/20 0.49
BRD4 O60885 1/20 0.49
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
CCR8 P51685 1/20 0.48
NUDT1 P36639 2/20 0.47
PLK4 O00444 2/20 0.46
ROCK2 O75116 2/20 0.46
PRKD3 O94806 2/20 0.46
MAP4K4 O95819 2/20 0.46
INSR P06213 2/20 0.46
CDK1 P06493 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13854134 0.80 CDK8 (0.65) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL15871324 0.80 RIPK1 (0.71) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL4831501 0.78 CDK8 (0.81) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL7995057 0.77 ULK1 (0.49) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL23655689 0.77 CDK8 (0.56) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL22766181 0.76 CDK8 (0.51) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL8488599 0.76 CDK8 (0.51) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL1683410 0.76 ULK1 (0.55) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL3348302 0.76 CDK8 (0.51) CDK8AXLPIK3CAPIK3CDPIK3CB
SCHEMBL857038 0.76 CDK8 (0.69) CDK8AXLPIK3CAPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 912 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734516-B1 ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BOEHRINGER INGELHEIM INT (DE) 2015-06-17 EP claimed
EP-4692089-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR Alicorn Pharmaceutical Co., Ltd. (CN) 2026-02-11 EP disclosed
US-20250361233-A1 Compounds For Activating Serotonin Receptor Psylo Pty Ltd (AU) 2025-11-27 US disclosed
US-12415804-B2 Compounds for activating a serotonin receptor Psylo Pty Ltd (AU) 2025-09-16 US disclosed
US-20250206739-A1 Compounds Psylo Pty Ltd (AU) 2025-06-26 US disclosed
US-20250163044-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-05-22 US disclosed
CN-118974044-A Compounds of formula (I) 赛洛私人有限公司 2024-11-15 CN disclosed
EP-4452979-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 EP disclosed
CN-118772152-A Azacyclic compounds as AAK1 inhibitors 艾立康药业股份有限公司 2024-10-15 CN disclosed
WO-2024207945-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AS AAK1 INHIBITOR 艾立康药业股份有限公司 2024-10-10 WO disclosed
WO-2006026754-A2 BICYCLIC HETEROARYL PDE4B INHIBITORS PLEXXIKON, INC. (US) 2006-03-09 WO disclosed
WO-2004108892-A2 1,1-DISUBSTITUTEDCYCLOALKYL-, GLYCINAMIDYL-, SULFONYL-AMIDINO-, AND TETRAHYDROPYRIMIDINYL-CONTAINING DIAMINOALKYL, β-AMINOACIDS, α-AMINOACIDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-16 WO disclosed
WO-2004083174-A2 SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-30 WO disclosed
WO-2004078757-A2 SYNTHESIS OF 5-SUBSTITUTED 7-AZAINDOLES AND 7-AZAIDONINES EISAI CO., LTD. (JP) 2004-09-16 WO disclosed
WO-2004041776-A2 SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-21 WO disclosed
WO-2004037176-A2 QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-06 WO disclosed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO disclosed
WO-2003047520-A2 SUBSTITUTED AMINO METHYL FACTOR Xa INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 WO disclosed
WO-2003048081-A2 GLYCINAMIDES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-12 WO disclosed
WO-2003026652-A1 LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206739-A1 Compounds NLN, SLC18A2, PYGB CDK8 1581/4885AXL 4487/4885PIK3CA 2696/4885
US-12415804-B2 Compounds for activating a serotonin receptor HTR2C, HTR6, HTR2A CDK8 1407/4885AXL 2597/4885PIK3CA 1829/4885
US-20250361233-A1 Compounds For Activating Serotonin Receptor HTR2C, HTR2A, HTR6 CDK8 1147/4885AXL 2342/4885PIK3CA 1768/4885
US-20250163044-A1 COMPOUNDS NLN, SLC18A2, PYGB CDK8 1581/4885AXL 4487/4885PIK3CA 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.